Trending

Perjeta

Roche’s Herceptin/Perjeta combo product nears EU approval

Roche’s Herceptin/Perjeta combo product nears EU approval

The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin

X

Roche’s Herceptin/Perjeta combo product nears EU approval

https://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/

After a nay from NICE, Scotland says aye to J&J’s Spravato

After a nay from NICE, Scotland says aye to J&J’s Spravato

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug

X

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer

Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer

Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer

X

Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer

https://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/

Roche’s Perjeta combo approved in Europe for early breast cancer

Roche’s Perjeta combo approved in Europe for early breast cancer

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

X

Roche’s Perjeta combo approved in Europe for early breast cancer

https://pharmaphorum.com/news/roches-perjeta-approved-early-breast-cancer/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com